GlassScriptPhysician profile
Syed A Sadiq
NPI 1144211707
$9,264.33
in general payments reported to CMS, 2019-2025
46 companies · $2,097 in 2025
The $2,097 reported for 2025 was more than what 80% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,149 · 2020: $366 · 2021: $696 · 2022: $1,010 · 2023: $1,344 · 2024: $2,602 · 2025: $2,097.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,284 · Travel and Lodging: $706 · Education: $52.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,284.21 |
| Travel and Lodging | $706.02 |
| Education | $52.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,803.88 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Boston Scientific Corporation | $1,101.35 | 2023-2025 | Cre Pro, General - Therapies |
| Janssen Biotech, INC. | $901.92 | 2019-2025 | Stelara, Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $553.50 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Celgene Corporation | $439.88 | 2021-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $372.38 | 2021-2025 | Xifaxan, Trulance |
| Pfizer INC. | $260.64 | 2019-2025 | |
| Qol Medical, LLC | $225.93 | 2019-2025 | Sucraid, Sucraid |
| Regeneron Healthcare Solutions, INC. | $225.50 | 2022-2025 | Dupixent |
| Saluda Medical Americas, INC. | $216.99 | 2025 | Evoke |
| Madrigal Pharmaceuticals | $161.64 | 2024-2025 | Rezdiffra, Resmetirom |
| Ironwood Pharmaceuticals, INC | $146.12 | 2019-2024 | Linzess |
| Daiichi Sankyo INC. | $131.68 | 2019-2023 | Injectafer |
| Enterra Medical, INC. | $127.64 | 2024-2025 | |
| Lilly USA, LLC | $121.25 | 2023-2025 | Omvoh |
Show all 45 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$56,121.38 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Syed Sadiq listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.